Hair Loss Pill Clinical Good News Sends Related Stocks Soaring; Samick Pharm Up 17%+
Predicted impact: Low
Sector stocks rise on a peer's clinical news; not company's own filing.
Samik Pharm삼익제약
014950 · KOSDAQ · ₩014950 · 삼익제약
₩7,690▲ ₩670 (9.54%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −39.11%
- Market cap
- ₩78B
- Enterprise value
- ₩50B
- P/E
- —
- P/B
- 1.1×
- Dividend yield
- 0.5%
- ROE
- −1.8%
- Net margin
- −2.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−69.3% from the high
₩3,705Today: ₩7,050 – ₩8,250₩25,050
Returns
- 1W−8.0%
- 1M−26.3%
- 3M+85.7%
- 6M−22.5%
- YTD−45.0%
- 1Y−39.1%
- Volume today
- 4,400,245
- 2.0× the 20-day average
- Traded today
- ₩35B
- Listed shares
- 10,087,588
- EPS (12 months)
- −₩129
- Earnings yield −1.7%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+9.5% on Oct 28, 2026. Trading value 1.8× its normal.
- • Foreign investors sold a net ₩247M that day
- • Buzz 55 on JONBUR: heavy trading
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Normal- BuzzNormalBuzz 55: heavy trading.
- MomentumWeak-14.9% over the last month; the price is below its 20-day average.
- News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Samik Pharm stock overview
Samik Pharm (삼익제약, KRX: 014950) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops, manufactures and sells mainly prescription drugs, with synthetic pharmaceuticals as its core product type, and also runs a contract manufacturing (CMO) business. Its shares closed at ₩7,690 on Oct 28, 2026, up 9.54% on the day, giving it a market value of ₩78B.
Key facts
- Market cap
- ₩78B
- Sector
- Biotech & Pharma
- Latest price change
- +9.54%
- As of
- Oct 28, 2026
- Main business
- The company develops, manufactures and sells mainly prescription drugs, with synthetic pharmaceuticals as its core product type, and also runs a contract manufacturing (CMO) business.
Quick answers about Samik Pharm
- What does Samik Pharm do?
- The company develops, manufactures and sells mainly prescription drugs, with synthetic pharmaceuticals as its core product type, and also runs a contract manufacturing (CMO) business. Its main focus is treatments for hypertension, diabetes and hyperlipidemia, and it also offers over-the-counter products such as motion sickness medicine and cold medicine. Its products are sold through a network of distributors and CMO clients, and its operations are based in Korea.
- What is the market cap of Samik Pharm?
- The market capitalisation of Samik Pharm was ₩78B at the close on Oct 28, 2026.
- Who are the largest shareholders of Samik Pharm?
- According to the latest official filings, the largest reported holders are Lee Chung-hwan (59.44%, as of Oct 23, 2026); Lee Se-young (11.63%, as of Oct 31, 2025); Lee Yong-seok (10.90%, as of Oct 31, 2025).
- When is the next earnings report from Samik Pharm?
- Korean companies rarely announce results dates in advance. Based on when Samik Pharm filed the same report in past years, its next 2q results is expected around Oct 31, 2026.
Company profile
The company develops, manufactures and sells mainly prescription drugs, with synthetic pharmaceuticals as its core product type, and also runs a contract manufacturing (CMO) business. Its main focus is treatments for hypertension, diabetes and hyperlipidemia, and it also offers over-the-counter products such as motion sickness medicine and cold medicine. Its products are sold through a network of distributors and CMO clients, and its operations are based in Korea.
Written by AI from the company's latest annual report.
- Korean name
- 삼익제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 이충환
- Founded
- Jul 1980
- Listed
- Oct 2025
- Listed shares
- 10,087,588
- Fiscal year ends
- Month 12
- Website
- www.samik.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
[Stock Spotlight] Samick Pharm and Hyundai Pharm rise on US Veradermix hair-loss drug Phase 3 results
Predicted impact: Low
Stock move on a US peer's Phase 3 hair-loss result; not the company's own filing.
Recent filings
See all- 5%+ holding reportOct 23, 2026
- Investor relations (IR) eventOct 22, 2026
- Insider shareholding reportSep 23, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- 5%+ holding reportJul 6, 2026
Titles in Korean until English translations are added.
Also known as: Samik Pharm / 삼익제약 / 014950 / KRX:014950
Source: KRX statistical information